Elevated P-RBC complexes are associated with thrombotic risk and diagnostic potential in myeloproliferative neoplasms: a retrospective cohort study.
文献摘要
Background Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by excessive myeloid proliferation. The impaired clearance of senescent erythrocytes is a key pathological feature, yet its mechanisms remain unclear. Pro-phagocytic platelet-erythrocyte (P-RBC) complexes may represent a novel intercellular interaction involved in this process. Objective To investigate the levels of P-RBC complexes in MPN patients, their association with clinical characteristics and thrombotic risk, and their potential diagnostic value. Methods In this retrospective cohort study, 152 MPN patients (including polycythemia vera [PV], essential thrombocythemia [ET], and primary myelofibrosis [PMF]) and 152 healthy controls were enrolled. P-RBC complex levels in peripheral blood were measured using flow cytometry. Correlations with laboratory parameters, thrombotic events, and survival were analyzed. Results P-RBC complex levels were significantly higher in MPN patients than in controls (2.76 ± 0.53% vs. 1.28 ± 0.37%, P Conclusion P-RBC complexes are significantly elevated in MPN patients and correlate with disease subtype, inflammation, and thrombotic risk. They represent a promising novel biomarker for MPN diagnosis and risk stratification.